MaxCyte, Inc. (MXCT) - Cash per Share

MaxCyte, Inc. (MXCT) retains clients by integrating its technologies into FDA-approved biopharmaceutical protocols. The company seeks dominance in non-viral engineering by providing equipment and licenses to industry behemoths. The cash per share level indicates a value of 0.99, while the business relies on cyclical sales of high-margin cartridges for its systems.
Analytical breakdowns for MaxCyte, Inc.

Institutional capital assesses the attractiveness of MaxCyte, Inc. (MXCT) through the lens of the financial stability required for the global market expansion of Flow Electroporation licensing. By analyzing cash per share, which currently stands at 0.99, investors can determine the ratio of liquid reserves to the number of shares, allowing them to identify the burn rate and evaluate the asset's reliability amid operational expenses.